SanegeneBio Said to Weigh Hong Kong IPO Next Year After Confidential Filing

Stock News

Oct 08

SanegeneBio has reportedly submitted a listing application to the Hong Kong Stock Exchange on a confidential basis, with the goal of raising several hundred million US dollars through an IPO next year, according to reports. The company has appointed Morgan Stanley and CICC as joint sponsors.

Founded in 2021, SanegeneBio is focused on developing RNA interference (RNAi) therapies targeting autoimmune diseases, cardiovascular diseases, obesity and metabolic disorders. SanegeneBio states that RNAi technology can reversibly silence disease-causing genes. The company has R&D centers in Boston, Shanghai and Suzhou, and has so far initiated clinical trials for four experimental drugs.

SanegeneBio completed a US$110 million Series B financing round in December 2025, with participation from an international sovereign fund, SBP GROUP (01177) and Lake Bleu Capital, as well as a strategic investment from Eli Lilly. Existing shareholder Hillhouse Venture Capital and others also continued their support. In November 2025, the company completed a strategic collaboration with Eli Lilly on RNAi drug development strategy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hkg.itiger.com/news/1119194076"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119194076\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119194076?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-08 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119194076","market":"sg","top_or_hot":-1,"title":"SanegeneBio Said to Weigh Hong Kong IPO Next Year After Confidential Filing","media":"Stock News","content":"<p>SanegeneBio has reportedly submitted a listing application to the Hong Kong Stock Exchange on a confidential basis, with the goal of raising several hundred million US dollars through an IPO next year, according to reports. The company has appointed Morgan Stanley and CICC as joint sponsors.<br><br>Founded in 2021, SanegeneBio is focused on developing RNA interference (RNAi) therapies targeting autoimmune diseases, cardiovascular diseases, obesity and metabolic disorders. SanegeneBio states that RNAi technology can reversibly silence disease-causing genes. The company has R&D centers in Boston, Shanghai and Suzhou, and has so far initiated clinical trials for four experimental drugs.<br><br>SanegeneBio completed a US$110 million Series B financing round in December 2025, with participation from an international sovereign fund, <b>SBP GROUP</b> (01177) and Lake Bleu Capital, as well as a strategic investment from Eli Lilly. Existing shareholder Hillhouse Venture Capital and others also continued their support. In November 2025, the company completed a strategic collaboration with Eli Lilly on RNAi drug development strategy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SanegeneBio Said to Weigh Hong Kong IPO Next Year After Confidential Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanegeneBio Said to Weigh Hong Kong IPO Next Year After Confidential Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-08 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SanegeneBio has reportedly submitted a listing application to the Hong Kong Stock Exchange on a confidential basis, with the goal of raising several hundred million US dollars through an IPO next year, according to reports. The company has appointed Morgan Stanley and CICC as joint sponsors.<br><br>Founded in 2021, SanegeneBio is focused on developing RNA interference (RNAi) therapies targeting autoimmune diseases, cardiovascular diseases, obesity and metabolic disorders. SanegeneBio states that RNAi technology can reversibly silence disease-causing genes. The company has R&D centers in Boston, Shanghai and Suzhou, and has so far initiated clinical trials for four experimental drugs.<br><br>SanegeneBio completed a US$110 million Series B financing round in December 2025, with participation from an international sovereign fund, <b>SBP GROUP</b> (01177) and Lake Bleu Capital, as well as a strategic investment from Eli Lilly. Existing shareholder Hillhouse Venture Capital and others also continued their support. In November 2025, the company completed a strategic collaboration with Eli Lilly on RNAi drug development strategy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1521","symbol_name":"挪威政府全球养老基金持仓","start_time":0,"source_url":"","article_id":"1119194076","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119194076","pubTimestamp":1791457133,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SanegeneBio has reportedly submitted a listing application to the Hong Kong Stock Exchange on a confidential basis, with the goal of raising several hundred million US dollars through an IPO next...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1521":"挪威政府全球养老基金持仓","01177":"中国生物制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1589":"北水核心资产","BK1515":"抗疫概念","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1191":"制药"},"translate_title":"SanegeneBio 表示将在保密备案后考虑明年在香港 IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SanegeneBio has reportedly submitted a listing application to the Hong Kong Stock Exchange on a confidential basis, with the goal of raising several hundred million US dollars through an IPO next year, according to reports. The company has appointed Morgan Stanley and CICC as joint sponsors.Founded in 2021, SanegeneBio is focused on developing RNA interference (RNAi) therapies targeting autoimmune diseases, cardiovascular diseases, obesity and metabolic disorders. SanegeneBio states that RNAi technology can reversibly silence disease-causing genes. The company has R&D centers in Boston, Shanghai and Suzhou, and has so far initiated clinical trials for four experimental drugs.SanegeneBio completed a US$110 million Series B financing round in December 2025, with participation from an international sovereign fund, SBP GROUP (01177) and Lake Bleu Capital, as well as a strategic investment from Eli Lilly. Existing shareholder Hillhouse Venture Capital and others also continued their support. In November 2025, the company completed a strategic collaboration with Eli Lilly on RNAi drug development strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}